Total Payments
$4,215
2021 Payments
$26.08
Companies
12
Transactions
31
Medicare Patients
781
Medicare Billing
$90,524
Payment Breakdown by Category
Research$3,793 (90.0%)
Food & Beverage$395.92 (9.4%)
Education$26.08 (0.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,793 | 5 | 90.0% |
| Food and Beverage | $395.92 | 24 | 9.4% |
| Education | $26.08 | 2 | 0.6% |
Payments by Type
Research
$3,793
5 transactions
General
$422.00
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $3,793 | 5 | $0 (2020) |
| Janssen Biotech, Inc. | $117.09 | 7 | $0 (2019) |
| Genentech USA, Inc. | $70.51 | 5 | $0 (2017) |
| AbbVie, Inc. | $61.47 | 4 | $0 (2018) |
| Novocure Inc. | $59.78 | 1 | $0 (2019) |
| PFIZER INC. | $37.34 | 3 | $0 (2021) |
| Lilly USA, LLC | $15.66 | 1 | $0 (2017) |
| Pharmacyclics LLC, An AbbVie Company | $13.90 | 1 | $0 (2017) |
| Cardinal Health 414, LLC | $13.79 | 1 | $0 (2019) |
| Array BioPharma Inc. | $11.14 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $26.08 | 2 | PFIZER INC. ($26.08) |
| 2020 | $439.15 | 1 | Eli Lilly and Company ($439.15) |
| 2019 | $2,270 | 6 | Eli Lilly and Company ($2,171) |
| 2018 | $586.78 | 10 | Eli Lilly and Company ($442.50) |
| 2017 | $892.55 | 12 | Eli Lilly and Company ($739.99) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/11/2021 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2021 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 01/28/2020 | Eli Lilly and Company | — | — | In-kind items and services | $439.15 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 08/30/2019 | Cardinal Health 414, LLC | — | Food and Beverage | In-kind items and services | $13.79 | General |
| 08/12/2019 | Array BioPharma Inc. | Braftovi (Drug), Mektovi | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: Melanoma | ||||||
| 04/04/2019 | Novocure Inc. | Oncology (Device) | Food and Beverage | Cash or cash equivalent | $59.78 | General |
| Category: Optune | ||||||
| 02/13/2019 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Oncology | ||||||
| 01/28/2019 | Eli Lilly and Company | — | — | In-kind items and services | $836.13 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 01/22/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,335.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 12/12/2018 | Teva Pharmaceuticals USA, Inc. | BENDEKA (Drug) | Food and Beverage | In-kind items and services | $10.60 | General |
| Category: Oncology | ||||||
| 11/13/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Virology | ||||||
| 10/30/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Oncology | ||||||
| 09/12/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Oncology | ||||||
| 09/05/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Virology | ||||||
| 08/23/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: Oncology | ||||||
| 05/09/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: Virology | ||||||
| 04/05/2018 | Eli Lilly and Company | — | — | In-kind items and services | $442.50 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 02/22/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: Oncology | ||||||
| 02/12/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: Virology | ||||||
| 12/21/2017 | Eli Lilly and Company | — | — | In-kind items and services | $739.99 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 11/16/2017 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: Oncology | ||||||
| 09/21/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $11.26 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/18/2017 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Oncology | ||||||
| 06/05/2017 | Genentech USA, Inc. | Perjeta (Biological), Kadcyla | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: BioOncology | ||||||
| 05/17/2017 | Lilly USA, LLC | ERBITUX (Drug), CYRAMZA, LARTRUVO | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $3,793 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 380 | 654 | $86,374 | $52,466 |
| 2020 | 5 | 401 | 716 | $76,897 | $38,057 |
Total Patients
781
Total Services
1,370
Medicare Billing
$90,524
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 116 | 226 | $38,072 | $25,453 | 66.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 201 | 340 | $40,902 | $23,652 | 57.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 26 | 29 | $2,251 | $1,232 | 54.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 20 | $2,575 | $1,133 | 44.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 21 | 39 | $2,574 | $995.67 | 38.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 222 | 463 | $53,106 | $26,710 | 50.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 123 | 162 | $11,889 | $5,394 | 45.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 29 | 48 | $7,876 | $4,192 | 53.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 20 | $2,392 | $1,092 | 45.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 15 | 23 | $1,634 | $668.13 | 40.9% |
About Dr. James Radford, MD
Dr. James Radford, MD is a Hematology & Oncology healthcare provider based in Hendersonville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477515195.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Radford, MD has received a total of $4,215 in payments from pharmaceutical and medical device companies, with $26.08 received in 2021. These payments were reported across 31 transactions from 12 companies. The most common payment nature is "" ($3,793).
As a Medicare-enrolled provider, Radford has provided services to 781 Medicare beneficiaries, totaling 1,370 services with total Medicare billing of $90,524. Data is available for 2 years (2020–2021), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Hendersonville, NC
- Active Since 04/06/2006
- Last Updated 03/31/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1477515195
Products in Payments
- DARZALEX (Biological) $103.27
- Venclexta (Drug) $61.47
- Oncology (Device) $59.78
- Perjeta (Biological) $39.32
- TECENTRIQ (Biological) $31.19
- BRAFTOVI (Drug) $26.08
- ERBITUX (Drug) $15.66
- Imbruvica (Drug) $13.90
- IMBRUVICA (Drug) $13.82
- ELIQUIS (Drug) $11.26
- Braftovi (Drug) $11.14
- Xtandi (Drug) $10.72
- BENDEKA (Drug) $10.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Hendersonville
Don Jackson, Md, MD
Hematology & Oncology — Payments: $9,409
Hematology & Oncology $9,409
John Hill, Md, MD
Hematology & Oncology — Payments: $5,848
Hematology & Oncology $5,848
Dr. Douglas Thompson, M.d, M.D
Hematology & Oncology — Payments: $4,629
Hematology & Oncology $4,629
Laura Mcclure Barnes, M.d, M.D
Hematology & Oncology — Payments: $3,802
Hematology & Oncology $3,802
Mr. Alexander Tremont, Do, DO
Hematology & Oncology — Payments: $1,661
Hematology & Oncology $1,661
Dr. William Butler, Md, MD
Hematology & Oncology — Payments: $1,483
Hematology & Oncology $1,483